Farmers & Merchants Investments Inc. maintained its position in Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 53,535 shares of the medical technology company’s stock at the end of the second quarter. Farmers & Merchants Investments Inc.’s holdings in Stryker Corporation were worth $7,430,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in SYK. Macquarie Group Ltd. increased its position in Stryker Corporation by 13.3% in the fourth quarter. Macquarie Group Ltd. now owns 103,000 shares of the medical technology company’s stock valued at $12,341,000 after buying an additional 12,100 shares during the period. Gulf International Bank UK Ltd increased its position in Stryker Corporation by 1.3% in the first quarter. Gulf International Bank UK Ltd now owns 104,546 shares of the medical technology company’s stock valued at $13,763,000 after buying an additional 1,300 shares during the period. Lynch & Associates IN increased its position in Stryker Corporation by 0.3% in the first quarter. Lynch & Associates IN now owns 27,450 shares of the medical technology company’s stock valued at $3,614,000 after buying an additional 75 shares during the period. Koshinski Asset Management Inc. increased its position in Stryker Corporation by 428.5% in the first quarter. Koshinski Asset Management Inc. now owns 15,991 shares of the medical technology company’s stock valued at $2,105,000 after buying an additional 12,965 shares during the period. Finally, National Pension Service increased its position in Stryker Corporation by 0.4% in the first quarter. National Pension Service now owns 245,638 shares of the medical technology company’s stock valued at $32,412,000 after buying an additional 884 shares during the period. 73.79% of the stock is currently owned by institutional investors and hedge funds.
Stryker Corporation (NYSE:SYK) traded down 0.74% on Friday, reaching $144.29. The company’s stock had a trading volume of 1,673,285 shares. The firm has a 50-day moving average of $144.61 and a 200 day moving average of $136.38. Stryker Corporation has a 12-month low of $106.48 and a 12-month high of $148.84. The company has a market capitalization of $53.97 billion, a price-to-earnings ratio of 32.21 and a beta of 0.80.
Stryker Corporation (NYSE:SYK) last issued its earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The firm had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.98 billion. During the same quarter last year, the firm earned $1.39 earnings per share. The firm’s revenue for the quarter was up 6.1% compared to the same quarter last year. On average, equities research analysts anticipate that Stryker Corporation will post $6.50 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be issued a $0.425 dividend. This represents a $1.70 dividend on an annualized basis and a yield of 1.18%. The ex-dividend date is Thursday, September 28th. Stryker Corporation’s payout ratio is currently 37.95%.
TRADEMARK VIOLATION WARNING: This report was first posted by BNB Daily and is the property of of BNB Daily. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/farmers-merchants-investments-inc-has-7430000-stake-in-stryker-corporation-nysesyk-updated.html.
Several brokerages recently commented on SYK. Stifel Nicolaus boosted their target price on shares of Stryker Corporation from $151.00 to $158.00 and gave the company a “buy” rating in a report on Friday, July 28th. BidaskClub cut shares of Stryker Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Goldman Sachs Group, Inc. (The) began coverage on shares of Stryker Corporation in a report on Tuesday, May 16th. They set a “neutral” rating and a $129.00 target price on the stock. Cowen and Company set a $150.00 target price on shares of Stryker Corporation and gave the company an “outperform” rating in a report on Wednesday, April 26th. Finally, Barclays PLC restated a “sell” rating and set a $133.00 target price on shares of Stryker Corporation in a report on Thursday, April 27th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company’s stock. Stryker Corporation currently has a consensus rating of “Hold” and a consensus target price of $144.03.
In other Stryker Corporation news, insider Graham A. Mclean sold 1,124 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the transaction, the insider now directly owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Floyd sold 19,305 shares of the business’s stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total value of $2,790,730.80. The disclosure for this sale can be found here. Insiders sold 32,810 shares of company stock worth $4,754,958 in the last quarter. 7.40% of the stock is owned by insiders.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.